运用分子和药理学技术对人冠状动脉中的5-羟色胺受体进行特性分析。
Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques.
作者信息
Nilsson T, Longmore J, Shaw D, Pantev E, Bard J A, Branchek T, Edvinsson L
机构信息
Department of Internal Medicine, Lund University Hospital, Sweden.
出版信息
Eur J Pharmacol. 1999 May 7;372(1):49-56. doi: 10.1016/s0014-2999(99)00114-4.
5-Hydroxytryptamine (5-HT) can produce both vasoconstrictor and vasorelaxant effects in human coronary arteries and the response to 5-HT can be influenced by the presence of disease. The aim of the present study was to elucidate the 5-HT receptor subtypes responsible for mediating 5-HT-evoked contraction of human coronary arteries using pharmacological, molecular and immunocytochemical approaches. Normal human coronary arteries, with intact endothelium, were mounted in tissue baths, and the vascular responses to 5-HT and 5-HT receptor agonists were studied. The effects of 5-HT1 and 5-HT2 receptor antagonists on these responses were also studied. Expression of messenger ribonucleic acid (mRNA) encoding different 5-HT receptors in human coronary arteries, atrium, ventricle wall and epicardium was determined using reverse transcriptase-polymerase chain reaction (RT-PCR) and Southern blot analysis. The expression of 5-HT1B or 5-HT1D receptor protein was studied using subtype selective antibodies and standard immunocytochemical techniques. The rank order of 5-HT receptor agonist potency in causing vasoconstriction was 5-carboxamido tryptamine, (5-CT) > zolmitriptan = BW183C91 (N10-desmethyl zolmitriptan) = alpha-methyl-5-hydroxytryptamine (alpha-CH3-5-HT) = 5-HT = sumatriptan > 2-methyl-5-hydroxytryptamine (2-CH3-5-HT) = 8-hydroxy-DPAT (8-OH-DPAT). Alpha-CH3-5-HT, 5-CT, 5-HT, zolmitriptan and BW 183C91 were significantly more potent (approximately 3-fold) than sumatriptan and 2-CH3-5-HT, which in turn were more potent than 8-OH-DPAT. Ketanserin and methiothepin (5-HT2 and 5-HT1 receptor antagonists, respectively) caused parallel rightward shifts of the concentration-effect curves to alpha-CH3-5-HT or 5-CT, respectively, without changing the maximum contractile response. In human coronary arteries, atrium. ventricle and epicardium. RT-PCR products corresponding to the human 5-HT2A, 5-HT1B and 5-HT1F receptors were expressed in high levels, mRNAs coding for 5-HT7, 5-HT1A and 5-HT1D receptors were only weakly expressed. No 5-HT1F receptor mRNA was detected. In coronary arteries there was a differential expression of 5-HT1B versus 5-HT1D receptor mRNAs, with 5-HT1B mRNAs being found in greater abundance. Dense 5-HT1B-immunoreactivity was detected on smooth muscle layer within coronary artery, however, 5-HT1D-immunoreactivity was not detected. It is concluded that 5-HT-evoked contraction of human coronary arteries is most probably mediated via the activation of both 5-HT1B and 5-HT2A receptors.
5-羟色胺(5-HT)可在人冠状动脉中产生血管收缩和血管舒张作用,且对5-HT的反应会受到疾病存在的影响。本研究的目的是采用药理学、分子生物学和免疫细胞化学方法,阐明介导5-HT诱发人冠状动脉收缩的5-HT受体亚型。将具有完整内皮的正常人冠状动脉安装在组织浴槽中,研究血管对5-HT和5-HT受体激动剂的反应。还研究了5-HT1和5-HT2受体拮抗剂对这些反应的影响。使用逆转录聚合酶链反应(RT-PCR)和Southern印迹分析,测定人冠状动脉、心房、心室壁和心外膜中编码不同5-HT受体的信使核糖核酸(mRNA)的表达。使用亚型选择性抗体和标准免疫细胞化学技术研究5-HT1B或5-HT1D受体蛋白的表达。5-HT受体激动剂引起血管收缩的效价顺序为5-羧酰胺色胺(5-CT)>佐米曲普坦=BW183C91(N10-去甲基佐米曲普坦)=α-甲基-5-羟色胺(α-CH3-5-HT)=5-HT=舒马曲坦>2-甲基-5-羟色胺(2-CH3-5-HT)=8-羟基-DPAT(8-OH-DPAT)。α-CH3-5-HT、5-CT、5-HT、佐米曲普坦和BW 183C91的效力明显更强(约3倍),高于舒马曲坦和2-CH3-5-HT,而舒马曲坦和2-CH3-5-HT又比8-OH-DPAT更有效。酮色林和甲硫噻平(分别为5-HT2和5-HT1受体拮抗剂)分别使α-CH3-5-HT或5-CT的浓度-效应曲线平行右移,而不改变最大收缩反应。在人冠状动脉、心房、心室和心外膜中,与人类5-HT2A、5-HT1B和5-HT1F受体相对应的RT-PCR产物高水平表达,编码5-HT7、5-HT1A和5-HT1D受体的mRNA仅弱表达。未检测到5-HT1F受体mRNA。在冠状动脉中,5-HT1B与5-HT1D受体mRNA存在差异表达,5-HT1B mRNA含量更丰富。在冠状动脉平滑肌层检测到密集的5-HT1B免疫反应性,然而,未检测到5-HT1D免疫反应性。结论是,5-HT诱发的人冠状动脉收缩很可能是通过5-HT1B和5-HT2A受体的激活介导的。